FDA Final PDURS Guidance: Paving the Way for Drug + Digital ClinDev Strategy

regulatory
digital health
clinical development
FDA’s final guidance on prescription drug use-related software treats sponsor-provided companion apps as drug labeling. Early thoughts on evidence planning and the drug lifecycle.
Author

Abhishek (Abhi) Pratap

Published

November 1, 2026

FDA has released its final guidance on prescription drug use-related software (PDURS).

The short version: FDA acknowledges that

“…various software … mobile apps … may have a variety of health-related uses, such as assisting patients with tracking their own drug administration, providing individualized dosing recommendations, predicting treatment response, and managing side effects…”

So what does this mean? Sponsor-provided “companion apps” that show benefit to patients and clinicians count as drug labeling, either FDA-required or promotional.

This may open some interesting questions about where companion apps fit in evidence planning, and how they might evolve over a drug’s lifecycle.

I put together a few early thoughts in the slides below (and, admittedly, AI is getting suspiciously good at turning my thoughts into slides).

Slide 1: Companion apps could become part of ClinDev strategy. What FDA's final guidance on prescription drug use-related software means for clinical developers. Slide 2: Two kinds of labeling, FDA-required and promotional, compared on where, entry, updates and value. Evidence largely decides which one applies. Slide 3: A claim that's hard to replicate. Randomize the drug plus the app against the drug alone; an improved clinical outcome can be described in the label. Slide 4: Potential differentiation. A drug's label can mention a paired app even without outcome data. Slide 5: A new chapter for an established brand. Outcome data for an app could support a new labeling claim after approval. Slide 6: More flexible routes to the evidence: a pragmatic trial, a decentralized trial, or an add-on arm inside a broader program. Slide 7: Clearer guidance to plan around: a decision tree for labeling, a defined 'by or on behalf of' a sponsor, a PDURS type on Form FDA 2253, and sample label wording. Slide 8: Some practical questions to work through: development, deployment, lifecycle and ownership. Slide 9: These are early views. The topic needs more voices: clinical development, regulatory, patients and families, and payers.
1 / 9 download pdf

This topic would benefit from many perspectives: clinical development, regulatory, patients and families, and payers. What am I missing? I’d welcome your views; you can reach me on LinkedIn.

Views are my own.